Patient, disease, and transplantation characteristics
| Characteristic . | Total . | Normal/mild . | Moderate . | Severe . |
|---|---|---|---|---|
| No. of patients | 152 | 47 | 48 | 57 |
| Age, y [median (range)] | 51 (1-66) | 46 (1-65) | 49 (3-65) | 47 (3-66) |
| Sex, M/F, no. of patients | 89/63 | 24/23 | 32/16 | 33/24 |
| Follow-up, y [median (range)] | 2.4 (1-5) | 2.3 (1-5) | 2.2 (1-5) | 2.6 (1-5) |
| Time from diagnosis to transplantation, d [median (range)] | 252 (17-4755) | 362 (17-4380) | 212 (49-1601) | 233 (84-4755) |
| WHO stage, no. (%) of patients | ||||
| RA | 24 (16) | 15 (32) | 7 (15) | 2 (4) |
| RARS/RCMD-RS | 7 (5) | 4 (9) | 3 (6) | 0 (0) |
| RCMD | 24 (16) | 10 (21) | 7 (15) | 7 (12) |
| MDS-U | 10 (7) | 5 (11) | 4 (8) | 1 (2) |
| 5q- | 6 (4) | 4 (9) | 2 (4) | 0 |
| RAEB-1 | 31 (20) | 5 (11) | 7 (15) | 19 (33) |
| RAEB-2 | 23 (15) | 1 (2) | 9 (19) | 13 (23) |
| tAML | 27 (18) | 3 (6) | 9 (19) | 15 (26) |
| IPSS risk group, no. (%) of patients | ||||
| Low | 9 (6) | 8 (17) | 1 (2) | 0 (0) |
| Intermediate-1 | 78 (51) | 28 (60) | 28 (58) | 22 (39) |
| Intermediate-2 | 39 (26) | 9 (19) | 13 (27) | 17 (30) |
| High | 26 (17) | 2 (4) | 6 (13) | 18 (31) |
| Cytogenetic risk group, no. (%) of patients | ||||
| Good | 66 (43) | 22 (47) | 23 (48) | 21 (37) |
| Intermediate | 46 (30) | 13 (28) | 16 (33) | 17 (30) |
| Poor | 40 (27) | 12 (25) | 9 (19) | 19 (33) |
| GVHD prophylaxis | ||||
| MTX/CSP | 122 (80) | 41 (87) | 36 (75) | 45 (79) |
| MTX/FK506 | 17 (11) | 5 (11) | 7 (15) | 5 (9) |
| CSP/MMF | 4 (3) | 0 | 2 (4) | 2 (4) |
| MTX/CSP/rapamycin | 7 (5) | 1 (2) | 2 (4) | 4 (6) |
| CSP/rapamycin | 2 (1) | 0 | 1 (2) | 1 (2) |
| Related donor | 65 (43) | 21 (45) | 22 (46) | 22 (39) |
| HLA-identical sibling | 62 (41) | 19 (41) | 22 (46) | 21 (37) |
| HLA-matched family member | 3 (2) | 2 (4) | 0 | 1 (2) |
| Unrelated donor | 87 (57) | 26 (55) | 26 (54) | 35 (61) |
| HLA-matched | 60 | 17 (36) | 19 (40) | 24 (42) |
| HLA-mismatched | 27 | 9 (19) | 7 (14) | 11 (19) |
| Source of stem cells | ||||
| Peripheral blood | 129 (85) | 38 (81) | 43 (90) | 48 (84) |
| Marrow | 21 (14) | 9 (19) | 4 (8) | 8 (14) |
| Cord blood | 2 (1) | 0 | 1 (2) | 1 (2) |
| Conditioning regimen | ||||
| tBuCy | 120 (79) | 37 (79) | 36 (75) | 47 (83) |
| BuFlu | 27 (18) | 9 (19) | 10 (21) | 8 (14) |
| CyTBI | 5 (3) | 1 (2) | 2 (4) | 2 (4) |
| Abnormal blast category | ||||
| Normal blasts ≤ 5% | 59 (39) | 42 (90) | 16 (33) | 1 (2) |
| Normal blasts > 5% | 2 (1) | 2 (4) | 0 | 0 |
| Abnormal blasts ≤ 5% | 31 (20) | 2 (4) | 16 (33) | 13 (23) |
| Abnormal blasts > 5% | 60 (40) | 1 (2) | 16 (33) | 43 (75) |
| BM myeloblast dyspoiesis | ||||
| Phenotypically normal | 61 (40) | 44 (94) | 16 (33) | 1 (2) |
| ≤ 5% abnormal | 31 (20) | 2 (4) | 16 (33) | 13 (23) |
| 5%-10% abnormal | 26 (17) | 1 (2) | 11 (23) | 14 (25) |
| 10%-20% abnormal | 27 (18) | 0 | 5 (10) | 7 (12) |
| > 20% abnormal | 7 (5) | 0 | 0 |
| Characteristic . | Total . | Normal/mild . | Moderate . | Severe . |
|---|---|---|---|---|
| No. of patients | 152 | 47 | 48 | 57 |
| Age, y [median (range)] | 51 (1-66) | 46 (1-65) | 49 (3-65) | 47 (3-66) |
| Sex, M/F, no. of patients | 89/63 | 24/23 | 32/16 | 33/24 |
| Follow-up, y [median (range)] | 2.4 (1-5) | 2.3 (1-5) | 2.2 (1-5) | 2.6 (1-5) |
| Time from diagnosis to transplantation, d [median (range)] | 252 (17-4755) | 362 (17-4380) | 212 (49-1601) | 233 (84-4755) |
| WHO stage, no. (%) of patients | ||||
| RA | 24 (16) | 15 (32) | 7 (15) | 2 (4) |
| RARS/RCMD-RS | 7 (5) | 4 (9) | 3 (6) | 0 (0) |
| RCMD | 24 (16) | 10 (21) | 7 (15) | 7 (12) |
| MDS-U | 10 (7) | 5 (11) | 4 (8) | 1 (2) |
| 5q- | 6 (4) | 4 (9) | 2 (4) | 0 |
| RAEB-1 | 31 (20) | 5 (11) | 7 (15) | 19 (33) |
| RAEB-2 | 23 (15) | 1 (2) | 9 (19) | 13 (23) |
| tAML | 27 (18) | 3 (6) | 9 (19) | 15 (26) |
| IPSS risk group, no. (%) of patients | ||||
| Low | 9 (6) | 8 (17) | 1 (2) | 0 (0) |
| Intermediate-1 | 78 (51) | 28 (60) | 28 (58) | 22 (39) |
| Intermediate-2 | 39 (26) | 9 (19) | 13 (27) | 17 (30) |
| High | 26 (17) | 2 (4) | 6 (13) | 18 (31) |
| Cytogenetic risk group, no. (%) of patients | ||||
| Good | 66 (43) | 22 (47) | 23 (48) | 21 (37) |
| Intermediate | 46 (30) | 13 (28) | 16 (33) | 17 (30) |
| Poor | 40 (27) | 12 (25) | 9 (19) | 19 (33) |
| GVHD prophylaxis | ||||
| MTX/CSP | 122 (80) | 41 (87) | 36 (75) | 45 (79) |
| MTX/FK506 | 17 (11) | 5 (11) | 7 (15) | 5 (9) |
| CSP/MMF | 4 (3) | 0 | 2 (4) | 2 (4) |
| MTX/CSP/rapamycin | 7 (5) | 1 (2) | 2 (4) | 4 (6) |
| CSP/rapamycin | 2 (1) | 0 | 1 (2) | 1 (2) |
| Related donor | 65 (43) | 21 (45) | 22 (46) | 22 (39) |
| HLA-identical sibling | 62 (41) | 19 (41) | 22 (46) | 21 (37) |
| HLA-matched family member | 3 (2) | 2 (4) | 0 | 1 (2) |
| Unrelated donor | 87 (57) | 26 (55) | 26 (54) | 35 (61) |
| HLA-matched | 60 | 17 (36) | 19 (40) | 24 (42) |
| HLA-mismatched | 27 | 9 (19) | 7 (14) | 11 (19) |
| Source of stem cells | ||||
| Peripheral blood | 129 (85) | 38 (81) | 43 (90) | 48 (84) |
| Marrow | 21 (14) | 9 (19) | 4 (8) | 8 (14) |
| Cord blood | 2 (1) | 0 | 1 (2) | 1 (2) |
| Conditioning regimen | ||||
| tBuCy | 120 (79) | 37 (79) | 36 (75) | 47 (83) |
| BuFlu | 27 (18) | 9 (19) | 10 (21) | 8 (14) |
| CyTBI | 5 (3) | 1 (2) | 2 (4) | 2 (4) |
| Abnormal blast category | ||||
| Normal blasts ≤ 5% | 59 (39) | 42 (90) | 16 (33) | 1 (2) |
| Normal blasts > 5% | 2 (1) | 2 (4) | 0 | 0 |
| Abnormal blasts ≤ 5% | 31 (20) | 2 (4) | 16 (33) | 13 (23) |
| Abnormal blasts > 5% | 60 (40) | 1 (2) | 16 (33) | 43 (75) |
| BM myeloblast dyspoiesis | ||||
| Phenotypically normal | 61 (40) | 44 (94) | 16 (33) | 1 (2) |
| ≤ 5% abnormal | 31 (20) | 2 (4) | 16 (33) | 13 (23) |
| 5%-10% abnormal | 26 (17) | 1 (2) | 11 (23) | 14 (25) |
| 10%-20% abnormal | 27 (18) | 0 | 5 (10) | 7 (12) |
| > 20% abnormal | 7 (5) | 0 | 0 |
Bu indicates busulfan; CSP, cyclosporine; Cy, cyclophosphamide; FK506, tacrolimus; Flu, fludarabine; MMF, mycophenolate mofetil; MTX, methotrexate; RA, refractory anemia; RARS/RCMD-RS, refractory anemia with ringed sideroblasts/refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RCMD, refractory anemia multilineage dysplasia; MDS-U, myelodysplastic syndrome, unclassified; RAEB, refractory anemia with excess blasts; tAML, acute myeloid leukemia with multilineage dysplasia tranformed from a previous diagnosis of myelodysplastic syndrome; and TBI, total body irradiation.